 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 GLOBE NEWSWIRE -- Molecular Partners AG SIX: MOLN; NASDAQ: MOLN, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. In addition, members of Molecular Partners management will participate in several upcoming investor events in Switzerland during January 2023. 